Introduction: Intravenous (IV) thrombolysis with alteplase (rt-PA) is effective in ischaemic
INTRODUCTION
Stroke is a common disease worldwide and a leading cause of death worldwide. (1) In Malaysia, stroke is the second most common cause of mortality and second leading cause of disease burden. (2, 3) In addition, it was the fifth most common cause of hospitalisation locally in 2015. (2, 4) Malaysia is a developing country in South East Asia with a multi-ethnic population of 28.3 million in 2010. (5) Approximately 91.8% of the population are Malaysian citizens and 8.2% are non-citizens. (5) The ethnic distribution of the country is as follows: Malays (63.1%), Chinese (24.6%), Indians (7.3%) and others (5.0%). (5) Intravenous (IV) thrombolysis with alteplase (rt-PA) is effective in the management of acute ischaemic stroke (AIS) patients. (6) The administration of rt-PA results in better functional outcome, usually measured by the modified Rankin scale (mRS). (6, 7) The number needed to treat for good functional outcome (mRS 0-1) when rt-PA is administered < 3 hours from symptom onset is 11. (7) Moreover, the number needed to treat for good outcome in the patients treated 3.0-4.5 hours from stroke onset is 20. (7) The Totaled Health Risks in Vascular Events (THRIVE) score is a valuable, internationally validated tool in predicting the prognosis in Western patients with AIS after thrombolysis. (8) A THRIVE score of 0-2 is associated with a better prognosis, whereas a score of 6-9 is associated with a poorer prognosis. (9) Our tertiary hospital started a stroke thrombolysis service in February 2012 and currently offers a 24-hour acute stroke thrombolysis service. However, to date, there has been no literature on the functional outcome of stroke patients administered with rt-PA in Malaysia. Hence, the primary objective of this study was to evaluate the predictors of functional outcome in Malaysian AIS patients who were treated with IV rt-PA. The secondary objective was to assess the clinical outcome of the thrombolysed stroke patients using the modified Rankin scale (mRS). We also aimed to examine the predictive value of THRIVE score in this thrombolysis cohort.
METHODS

This retrospective study was approved by the Institutional Ethics Committee of University of
Malaya Medical Centre (UMMC), Kuala Lumpur, Malaysia. We recruited patients who were admitted to UMMC, Kuala Lumpur, Malaysia, for AIS between February 2012 and August 2016.
The data of consecutive patients from the stroke thrombolysis registry was recorded.
The inclusion and exclusion criteria for stroke thrombolysis were based on the National 
Eligible patients were administered with standard dose IV rt-PA 0.9 mg/kg (maximum 90 mg) within 4.5 hours of symptom onset, based on United States Food and Drug Administrationapproved indications. (12) 10% was administered intravenously as bolus dose and the remaining dose was given by continuous infusion over one hour. NIHSS scores were recorded on admission and discharge. The clinical course and progress was documented. The mRS was used to evaluate the clinical outcome at three months. (13) An mRS score of 0-2 was classified as a good clinical outcome, whereas a score of 3-6 was categorised as a poor clinical outcome. An assessment of the THRIVE score was also made on admission, as the baseline score. (14) In this study, a THRIVE score of 0-2 was defined as a good prognosis and 3-5 was defined as a moderately good prognosis. A score of 6-9 was defined as a poor prognosis.
Haemorrhagic transformation post thrombolysis was graded according to the ECASS I (European Cooperative Acute Stroke Study I) criteria. (15) Symptomatic intracerebral haemorrhage (SICH) was defined as the presence of intracerebral haemorrhage with worsening of NIHSS score by > 4 points occurring within 48 hours of administration of rt-PA. (15) Delayed haemorrhage was defined as intracerebral haemorrhage occurring ≥ 48 hours after the administration of rt-PA. (16) Mortality due to any cause was also recorded.
Data was analysed using IBM SPSS Statistics version 19.0 (IBM Corp, Armonk, NY, USA). Numerical variables were expressed as median, mean ± standard deviation and range.
Categorical variables of patients' baseline characteristics were presented as percentages.
Continuous variables were analysed using the independent Student's t-test. Chi-square (or Fisher's exact test) was used to analyse the association between functional outcome and vascular risk factors. Multiple logistic regression analysis was performed to determine the predictors of functional outcome, and included variables that were statistically significant on univariate analysis. A two-tailed p-value < 0.05 was considered to be statistically significant.
RESULTS
The demographic characteristics and stroke subtypes are shown in Table I . During the study period, 38 patients received IV rt-PA. Two patients, who had an mRS score of 2 and 3 on discharge, were lost to follow-up at three months and were excluded from the study. A total of 400 patients with ischaemic stroke were admitted to the neurology ward annually. During the study period, 1,800 ischaemic stroke patients were admitted to the hospital. Hence, only 2.0% of these patients were treated with IV rt-PA. The median age of our study population was 59.0 (range 37-79) years, and 75.0% were men. Hypertension (83.3%) was the most common risk factor. The median NIHSS score was Among the 2 (5.6%) patients with SICH, 1 (2.8%) had parenchymal haematoma (PH) Type 2 and 1 (2.8%) had haemorrhagic infarction (HI) Type 1. 5 (13.9%) patients had delayed intracerebral haemorrhage; 2 (5.6%) had PH Type 1, 2 (5.6%) had PH Type 2 and 1 (2.8%) patient had HI Type 1. The median mRS score at three months was 2 (range 0-6), with 16 (44.4%) patients scoring 0-1 and 20 (55.6%) patients scoring 0-2. The median THRIVE score was 3 (range 0-7), with 10 (27.8%) patients scoring 0-2, 21 (58.3%) patients scoring 3-5 and 5 (13.9%) patients scoring 6-9 ( Table I ).
The in-hospital mortality rate was 11.1% (n = 4). One patient died due to SICH, while three other patients died secondary to acute coronary syndrome within the first seven days of hospitalisation. No other patient died within the first three months after discharge. Table II shows the results of univariate analysis of good and poor functional outcomes.
Compared to those with poor outcomes, the patients with good outcomes had a lower mean NIHSS score (16.69 ± 6.66 vs. 12.05 ± 4.79; p = 0.03) and a lower mean THRIVE score (4.31 ± 2.02 vs. 2.90 ± 1.21; p = 0.02). Among the 20 patients with good outcomes, there was a higher proportion (90.0%, n = 18) of patients with non-cardioembolic stroke (i.e. large artery disease and lacunar stroke), compared to 2 (10.0%) patients with cardioembolic stroke (p = 0.049). In the group with good outcomes, there was also a higher proportion of patients without DM (75.0%, n = 15) compared to only 25.0% (n = 5) of patients with DM (p = 0.06). 
THRIVE: Totaled Health Risks in Vascular Events
There was no statistically significant association between functional outcome and the risk factors of age, gender, ethnicity, hypertension, hyperlipidaemia, history of smoking, atrial fibrillation, ischaemic heart disease, onset-to-treatment time, blood glucose level before thrombolysis and presence of intracerebral haemorrhage on univariate analysis. Multiple logistic regression (Table III) showed that functional outcome had a statistically significant association with NIHSS score before rt-PA (p = 0.032) and DM (p = 0.010). 
DISCUSSION
As stroke thrombolysis is a new and limited service in Malaysia, the data in this paper will be useful to help in the expansion of the current service. It could also assist in the development of similar services in other hospitals in Malaysia. Our findings show that stroke thrombolysis is safe, with similar outcomes in terms of functional status, SICH and mortality to those in the published literature. In our study, 44.4% of our patients had a three-month mRS score of 0-1 (i.e. excellent outcome), corresponding to other published data in Asia (26.1%-59.0%). (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) In the studies conducted in Europe and Canada, a three-month mRS score of 0-1 was observed in 31%-53% of the patients. (27) (28) (29) (30) SICH occurred in 5.6% of the patients, which was also similar to the previous literature. In studies in the Far East, SICH rates ranged from 3.1% to 7.0%. (24, 25, 31) In
Vietnam, SICH occurred in 5.5% of the patients. (20) In this study, the three-month mortality rate of 11.1% was comparable with previous studies that reported three-month mortality rates of 6.5%-15.0%. (7, 20, 24, 25, (32) (33) (34) However, our inhospital mortality rate was higher than the percentage reported in Singapore (3.7%). (7, 17) Another multi-centre study had a one-week mortality rate of 1.5%.
The prognostic factors identified in this study were DM and baseline NIHSS score, a finding that was consistent with the published literature. (17, 18, 24, (35) (36) (37) The THRIVE score at baseline was associated with functional outcome at three months, proving its utility for prognostication in this cohort. There is presently limited data on THRIVE scoring among Asians.
To our knowledge, this study is the second study on the evaluation of thrombolysed stroke patients in Asia with the THRIVE score. The first study in Asia evaluated the usefulness of the score in predicting prognosis in Chinese stroke patients treated with rt-PA. (38) THRIVE score strongly predicts prognosis, with an increased score suggesting a higher risk of poor prognosis after stroke thrombolysis. (8, 39, 40) It is superior to the other outcome scoring systems such as HIAT (Houston Intra-Arterial Therapy), HIAT-2, HAT (Haemorrhage After Thrombolysis) and SPAN-100 (Stroke Prognostication Using Age and NIHSS-100) in the prediction of prognosis and mortality. (8) Moreover, the THRIVE score is a good predictor of intracerebral hemorrhage after rt-PA administration at three months. (8, 39, 40) The fact that it is simple to use also makes it a suitable instrument for developing Asian countries.
The main strength of this study was the use of known measures and THRIVE scores, which allowed for comparison with the published literature. Its main limitation was the small sample size consisting of only patients from a single urban hospital, resulting in our statistical results being less than robust. The small sample size was due to transportation challenges and the health-seeking behaviour of the patients in Kuala Lumpur, Malaysia.
In conclusion, in our newly established service, intravenous rt-PA was safe with a SICH rate of 5.6% and had similar functional outcomes compared to the literature from this region.
Poor functional outcome was associated with higher baseline NIHSS scores and the presence of DM. The THRIVE score was predictive of patients' final functional status.
